Previous close | 766.68 |
Open | 768.90 |
Bid | 776.64 x 1100 |
Ask | 776.89 x 900 |
Day's range | 762.11 - 779.09 |
52-week range | 419.80 - 800.78 |
Volume | |
Avg. volume | 2,917,136 |
Market cap | 739.197B |
Beta (5Y monthly) | 0.37 |
PE ratio (TTM) | 114.04 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.20 (0.68%) |
Ex-dividend date | 15 May 2024 |
1y target est | N/A |
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
Eli Lilly and Company (NYSE: LLY) today announced its financial results for the first quarter of 2024.
Eli Lilly and Company (NYSE: LLY) today announced positive topline results of the SURMOUNT-OSA phase 3 clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints. Percentage change in AHI was a key secondary endpoint in both studies. AHI records the number of times a person's breathing shows a restricted or complete block of airflow per hour of sleep and is used to evaluate the sever